Company intelligence / Profile preview

Quivive Pharma

San Diego, California, United Statesquivivepharma.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Quivive Pharma has demonstrated proof-of-concept in animal studies and is advancing its lead product, QEV‑817—a fixed-dose combination of hydrocodone bitartrate and doxapram hydrochloride—into Phase 1 clinical trials. The company’s approach aims to reduce opioid-induced respiratory depression without compromising analgesia, offering both safety improvements and abuse deterrence. Clinical results are pending as the first-in-human study is not yet recruiting as of March 2025.

Therapeutic areas: PulmonologyNeurology
Modalities: Small molecules (specifically fixed-dose combinations of generic opioids and respiratory stimulants)
Industry: Biotech

Drug pipeline

1 asset

QEV-817

Unknown

Partnerships

Camargo Pharmaceutical Services (regulatory consulting & strategic development services for pipeline development under the US FDA’s Section 505(b)(2) pathway)

Beyond the preview

Go deeper on Quivive Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Quivive Pharma.

Explore the full profile